234 related articles for article (PubMed ID: 31924156)
1. Focusing on DNA Repair and Damage Tolerance Mechanisms in Mycobacterium tuberculosis: An Emerging Therapeutic Theme.
Mittal P; Sinha R; Kumar A; Singh P; Ngasainao MR; Singh A; Singh IK
Curr Top Med Chem; 2020; 20(5):390-408. PubMed ID: 31924156
[TBL] [Abstract][Full Text] [Related]
2. Recent updates on drug resistance in Mycobacterium tuberculosis.
Singh R; Dwivedi SP; Gaharwar US; Meena R; Rajamani P; Prasad T
J Appl Microbiol; 2020 Jun; 128(6):1547-1567. PubMed ID: 31595643
[TBL] [Abstract][Full Text] [Related]
3. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
Uddin R; Zahra NU; Azam SS
Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
[TBL] [Abstract][Full Text] [Related]
4. Tuberculosis treatment-shortening.
Singh V
Drug Discov Today; 2024 May; 29(5):103955. PubMed ID: 38548262
[TBL] [Abstract][Full Text] [Related]
5. Remembering the Host in Tuberculosis Drug Development.
Frank DJ; Horne DJ; Dutta NK; Shaku MT; Madensein R; Hawn TR; Steyn AJC; Karakousis PC; Kana BD; Meintjes G; Laughon B; Tanvir Z
J Infect Dis; 2019 Apr; 219(10):1518-1524. PubMed ID: 30590592
[TBL] [Abstract][Full Text] [Related]
6. Harnessing Biological Insight to Accelerate Tuberculosis Drug Discovery.
de Wet TJ; Warner DF; Mizrahi V
Acc Chem Res; 2019 Aug; 52(8):2340-2348. PubMed ID: 31361123
[TBL] [Abstract][Full Text] [Related]
7. Opportunities for overcoming tuberculosis: Emerging targets and their inhibitors.
Yang L; Hu X; Chai X; Ye Q; Pang J; Li D; Hou T
Drug Discov Today; 2022 Jan; 27(1):326-336. PubMed ID: 34537334
[TBL] [Abstract][Full Text] [Related]
8. Finding New Ways to Combat Multidrug-Resistant Tuberculosis.
Faridgohar M
Microb Drug Resist; 2020 Jan; 26(1):71-80. PubMed ID: 31517569
[TBL] [Abstract][Full Text] [Related]
9. Discovery of antitubercular 2,4-diphenyl-1H-imidazoles from chemical library repositioning and rational design.
Pieroni M; Wan B; Zuliani V; Franzblau SG; Costantino G; Rivara M
Eur J Med Chem; 2015 Jul; 100():44-9. PubMed ID: 26071857
[TBL] [Abstract][Full Text] [Related]
10. The significance of GlgE as a new target for tuberculosis.
Kalscheuer R; Jacobs WR
Drug News Perspect; 2010 Dec; 23(10):619-24. PubMed ID: 21180647
[TBL] [Abstract][Full Text] [Related]
11. New tuberculostatic agents targeting nucleic acid biosynthesis: drug design using QSAR approaches.
Bueno RV; Braga RC; Segretti ND; Ferreira EI; Trossini GH; Andrade CH
Curr Pharm Des; 2014; 20(27):4474-85. PubMed ID: 24245758
[TBL] [Abstract][Full Text] [Related]
12. Recent advances for identification of new scaffolds and drug targets for Mycobacterium tuberculosis.
Dhiman R; Singh R
IUBMB Life; 2018 Sep; 70(9):905-916. PubMed ID: 29761628
[TBL] [Abstract][Full Text] [Related]
13. [Frontier of mycobacterium research--host vs. mycobacterium].
Okada M; Shirakawa T
Kekkaku; 2005 Sep; 80(9):613-29. PubMed ID: 16245793
[TBL] [Abstract][Full Text] [Related]
14. Risk Factors for Multidrug-resistant Tuberculosis.
Rumende CM
Acta Med Indones; 2018 Jan; 50(1):1-2. PubMed ID: 29686169
[TBL] [Abstract][Full Text] [Related]
15. SAR analysis of new anti-TB drugs currently in pre-clinical and clinical development.
Poce G; Cocozza M; Consalvi S; Biava M
Eur J Med Chem; 2014 Oct; 86():335-51. PubMed ID: 25173852
[TBL] [Abstract][Full Text] [Related]
16. New perspectives on the treatment of mycobacterial infections using antibiotics.
He Y; Fan A; Han M; Zhang Y; Tong Y; Zheng G; Zhu S
Appl Microbiol Biotechnol; 2020 May; 104(10):4197-4209. PubMed ID: 32185432
[TBL] [Abstract][Full Text] [Related]
17. [Recent progress in mycobacteriology].
Okada M; Kobayashi K
Kekkaku; 2007 Oct; 82(10):783-99. PubMed ID: 18018602
[TBL] [Abstract][Full Text] [Related]
18. Tuberculosis clinical trial update and the current anti-tuberculosis drug portfolio.
Palomino JC; Martin A
Curr Med Chem; 2013; 20(30):3785-96. PubMed ID: 23862617
[TBL] [Abstract][Full Text] [Related]
19. Host Directed Therapies for Tuberculosis: Futures Strategies for an Ancient Disease.
Palucci I; Delogu G
Chemotherapy; 2018; 63(3):172-180. PubMed ID: 30032143
[TBL] [Abstract][Full Text] [Related]
20. Genetic diversity of Mycobacterium tuberculosis isoniazid monoresistant and multidrug-resistant in Rio Grande do Sul, a tuberculosis high-burden state in Brazil.
Esteves LS; Dalla Costa ER; Vasconcellos SEG; Vargas A; Ferreira Junior SLM; Halon ML; Ribeiro MO; Rodenbusch R; Gomes HM; Suffys PN; Rossetti MLR
Tuberculosis (Edinb); 2018 May; 110():36-43. PubMed ID: 29779771
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
